News
CABA
12.96
-2.70%
-0.36
Weekly Report: what happened at CABA last week (0415-0419)?
Weekly Report · 2d ago
Noteworthy Wednesday Option Activity: PINS, WYNN, CABA
NASDAQ · 04/17 19:24
Weekly Report: what happened at CABA last week (0408-0412)?
Weekly Report · 04/15 09:01
Weekly Report: what happened at CABA last week (0401-0405)?
Weekly Report · 04/08 09:01
Cabaletta Bio Price Target Maintained With a $50.00/Share by Cantor Fitzgerald
Dow Jones · 04/05 13:30
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target
Benzinga · 04/05 13:19
Cabaletta Bio Is Maintained at Buy by Citigroup
Dow Jones · 04/04 15:57
Cabaletta Bio Price Target Raised to $30.00/Share From $26.00 by Citigroup
Dow Jones · 04/04 15:57
Citigroup Maintains Buy on Cabaletta Bio, Raises Price Target to $30
Benzinga · 04/04 15:47
CABALETTA BIO INC <CABA.O>: CITIGROUP RAISES TARGET PRICE TO $30 FROM $26
Reuters · 04/04 10:09
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Cabaletta Bio (CABA)
TipRanks · 04/04 09:20
Weekly Report: what happened at CABA last week (0325-0329)?
Weekly Report · 04/01 09:01
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
TipRanks · 03/26 02:10
Cabaletta Bio Issued ID#NCT06328777 For Phase 1/2 Open-Label Study To Evaluate The Safety And Efficacy Of CABA-201, A CD19-CAR T Cell Therapy, In Subjects With Systemic Sclerosis Posted To Clinical Trials Website On 2024-03-25
Inclusion Criteria: A clinical diagnosis of SSc, based on the 2013 American College of Rheumatology and European League Against Rheumatism classification criteria. Exclusion criteria include history of anaphylactic or severe systemic reaction to leukapheresis or CAR T cell therapy.
Benzinga · 03/25 14:25
Weekly Report: what happened at CABA last week (0318-0322)?
Weekly Report · 03/25 09:01
Cabaletta Bio Price Target Maintained With a $50.00/Share by Cantor Fitzgerald
Dow Jones · 03/22 18:04
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target
Benzinga · 03/22 17:54
Cabaletta Bio Is Maintained at Overweight by Wells Fargo
Dow Jones · 03/22 17:50
Cabaletta Bio Price Target Raised to $35.00/Share From $34.00 by Wells Fargo
Dow Jones · 03/22 17:50
Wells Fargo Maintains Overweight on Cabaletta Bio, Raises Price Target to $35
Benzinga · 03/22 17:40
More
Webull provides a variety of real-time CABA stock news. You can receive the latest news about Cabaletta Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.